PureTech Health PLC - Boston, Massachusetts-based biotherapeutics company - Says founded entity Vor Biopharma has priced its initial public offering of 9.8 million shares at USD18.00 per share, resulting in gross proceeds of USD176.9 million. Notes Vor Biopharma filed for an IPO with the US Securities & Exchange Commission in January. Says shares to trade on the Nasdaq Global Market, with the offering expected to close next Tuesday. Goldman Sachs & Co LLC, Evercore ISI, Barclays and Stifel are acting as book runners for the offering. PureTech owns 3.2 million Vor shares, giving it a 9.0% stake following the IPO.
Current stock price: 369.50 pence
Year-to-date change: down 7.6%
By Zoe Wickens; firstname.lastname@example.org
Copyright 2021 Alliance News Limited. All Rights Reserved.